ALDEHYDE DEHYDROGENASE 2: A CRITICAL APPRAISAL OF ITS ROLE AS A MEDIATOR OF THE ACUTE AND SUSTAINED VASCULAR RESPONSES TO NITROGLYCERIN

K. Zhou,J. Parker

DOI: https://doi.org/10.1016/j.cjca.2018.07.156

IF: 6.614

2018-01-01

Canadian Journal of Cardiology

Abstract:The mechanism by which nitroglycerin (or glyceryl trinitrate, GTN) exerts its biologic effects has remained a mystery for decades. In recent years it has been reported that aldehyde dehydrogenase 2 (ALDH-2) is the only enzyme responsible for the bioactivation of GTN at therapeutically relevant concentrations. Furthermore, observations in animal models suggest that ALDH-2 mediated denitrification of GTN generates a free radical intermediate which inactivates ALDH-2 leading to nitrate tolerance. However, the impact of ALDH-2 on the development of GTN tolerance has not been investigated in humans. We studied healthy volunteers who were heterozygous (n=12) or homozygous (n=11) for the ALDH-2 Glu504Lys polymorphism, a mutation that markedly reduces ALDH-2 activity, as well as a group without the polymorphism (n=12). We examined the systemic hemodynamic responses to the acute administration of transdermal GTN (0.6 mg/hour) and following seven days of continuous transdermal GTN treatment. We also examined arterial forearm blood flow (FBF) responses to brachial artery infusions of GTN, acetylcholine as well as L-NMMA before and after seven days of continuous transdermal GTN therapy. The acute blood pressure responses to transdermal GTN were similar in all three groups. This initial hypotensive response was lost after sustained GTN therapy in all three groups, indicating the development of tolerance. Prior to sustained GTN treatment, the FBF response to intra-arterial GTN was significantly smaller in subjects with the ALDH-2 polymorphism as compared to those without, although the FBF response to acetylcholine was similar in the three genotype groups. Following seven days of sustained transdermal GTN therapy, the FBF responses to both intra-arterial GTN and acetylcholine were blunted in all 3 groups, indicating the development of both tolerance and endothelial dysfunction. Prior to GTN therapy, the FBF response to L-NMMA was similar in the three genotype groups. Following sustained transdermal GTN therapy, the response to L-NMMA was significantly reduced in the group without the polymorphism while, interestingly, the responses to L-NMMA in the polymorphism group remained unchanged. Our results demonstrate that ALDH-2 is not responsible for the acute, systemic hemodynamic responses to GTN nor is it responsible for the development of tolerance or endothelial dysfunction during sustained GTN exposure.